UroGen Pharma (URGN) Inventory (2016 - 2026)

UroGen Pharma (URGN) has reported Inventory for 10 consecutive years, with $20.9 million the latest figure, recorded in Q1 2026.

• Quarterly Inventory rose 175.64% year-over-year to $20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.9 million (up 175.64% YoY) and the FY2025 annual result came in at $16.5 million, up 78.43% from the prior year.
• Inventory rose to $20.9 million in Q1 2026 per URGN's latest filing, from $16.5 million in the prior quarter.
• Over the last five years, Inventory for URGN reached as high as $20.9 million in Q1 2026 and fell as low as $4.3 million in Q4 2022.
• A 5-year average of $7.8 million and a median of $7.1 million in 2025 frame the typical range for Inventory.
• Annual changes were most pronounced in 2022 — Inventory fell 10.49% — and 2026, when it jumped 175.64%.
• Year by year, Inventory stood at $4.3 million in 2022, then soared by 31.17% to $5.7 million in 2023, then soared by 62.65% to $9.2 million in 2024, then jumped by 78.43% to $16.5 million in 2025, then grew by 27.07% to $20.9 million in 2026.
• According to Business Quant data, Inventory over the past three periods registered $20.9 million, $16.5 million, and $8.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.